EGFR and lung adenocarcinoma: In total, 227 Asian patients with exon 19 EGFR-mutant lung adenocarcinoma and brain metastases were included (erlotinib: n = 112, mean age = 58.5 years [SD: 20.13]; gefitinib: n = 115, mean age = 58.4 years [SD: 19.52]), as summarized in Fig. 1.